Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
July 2016
-
Media ReleaseNovartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissanceChiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
-
Media ReleaseNovartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige WachstumsperspektivenDer Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
-
Media ReleaseAlcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopiaPresbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
-
Media ReleaseSandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseasesCommittee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Media ReleaseNew data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator productThe EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
June 2016
-
Media ReleaseNovartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Media ReleaseLargest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skinGlobal survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not…
-
Media ReleaseNovartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with XencorAgreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA CardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
-
Media ReleaseNovartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatmentNovartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
-
Media ReleaseNovartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten GenerationNovartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
-
Media ReleaseNovartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéenNovartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- …
- 100
- › Next page